By Business/Source
Currency:CNY
2025/FY
Stock NameRevenueRatio
神经介入业务422.78M59.31%
经导管瓣膜治疗业务290.09M40.69%
By Product
Currency:CNY
2025/FY
Stock NameRevenueRatio
神经介入业务422.78M59.31%
经导管瓣膜治疗业务290.09M40.69%
By Country/Region
Currency:CNY
2025/FY
Stock NameRevenueRatio
China712.87M100.00%
